Erratum

Erratum for the Perspective: “Imaging approaches to optimize molecular therapies” by R. Weissleder, M. C. Schwaiger, S. S. Gambhir, H. Hricak

+ See all authors and affiliations

Science Translational Medicine  14 Dec 2016:
Vol. 8, Issue 369, pp. 369er8
DOI: 10.1126/scitranslmed.aam5501

In the Perspective article “Imaging approaches to optimize molecular therapies,” the competing interests section was inadvertently not included in the final version. The following text has now been added to the Acknowledgments section of the Perspective:

Competing interests: R.W. is a co-founder of T2Biosystems and is a co-founder and on the Board of Directors of Lumicell. M.C.S. has received a departmental research grant from Siemens. H.H. has received a departmental research grant from GE Medical. S.S.G. is an adviser for Bracco Diagnostics, Cellsight Technologies, Click Diagnostics, CytomX Therapeutics Inc., Endra Inc., Gamma Medica, Grail Inc., ImagingAb, Infinitus, MagArray Inc., Ninepoint Medical, Philips Healthcare, Puretech, RefleXion Medical, Rio Imaging, Spectrum Dynamics, Vave, Verily, Visualsonics, and Vor Biopharma. S.S.G. is also a founder of Cellsight Technologies, Endra Inc., and Rio Imaging. S.S.G. has also received departmental research grants from GE Medical, Philips Medical, and Siemens. S.S.G. and H.H. are on the executive board of the International Society for Strategic Studies in Radiology.

Related Content

Navigate This Article